Investor Alert

Market Pulse Archives

Sept. 9, 2021, 7:27 a.m. EDT

Moderna says it has about $15 billion in cash, working on combined COVID/seasonal flu booster

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    SPDR S&P Biotech ETF (XBI)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Moderna Inc. /zigman2/quotes/205619834/composite MRNA -11.87% said Thursday it had a cash position of about $15 billion as of Aug. 31. The company made the disclosure as it offered an update on its line of product candidates based on mRNA technology, that includes a vaccine against COVID-19, the first Moderna product to win authorization from the U.S. Food and Drug Administration. In a statement released ahead of an R&D day, the company highlighted a new product candidate that would combine a COVID-19 booster with a seasonal flu booster vaccine. The company recently submitted an application to the FDA for approval of its COVID booster shot, and said it saw "robust antibody responses" in a Phase 2 study. Overall, the company has 37 programs in development across 34 development candidates, including 22 in current clinical studies. Shares were flat premarket, but have gained 305% in the year to date, while the SPDR S&P Biotech ETF /zigman2/quotes/205950134/composite XBI -3.56% has fallen 6% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.18% has gained 20%.

US : U.S.: Nasdaq
$ 310.61
-41.82 -11.87%
Volume: 21.60M
Dec. 1, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$142.89 billion
Rev. per Employee
US : U.S.: NYSE Arca
$ 112.13
-4.14 -3.56%
Volume: 9.98M
Dec. 1, 2021 4:00p
-53.96 -1.18%
Volume: 3.04B
Dec. 1, 2021 5:04p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.